Ledipasvir 90 mg and Sofosbuvir 400 mg ( Harvoni) Trade Information
Brand name: Ledifos
Genric name: Ledipsavir & sofosbuvir
Genric strength:Ledipsavir 90 mg & sofosbuvir 400mg
packing: In bottle
Each bottle: 28 tablets
Marketing by : Hetero
storage below 25 degree
|Minimum Order Quantity||1.00||Unit of Measure||Piece/Pieces|
|Payment Terms||Paypal, Others||Supply Ability||As Per Requirement Per Week|
|Delivery Time||7-15 Days||Packaging Details||Carton Boxes Packaging|
|Main Export Market(s)||Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Africa,Russia,china, taiwaan||Main Domestic Market||All India|
We have uniquely positioned ourselves as a dependable firm, engaged in offering Ledipasvir 90 mg and Sofosbuvir 400 mg. These tablets are indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. We procure these tablets from the certified vendors of the market. The tablets are packed in moisture proof materials to ensure safe transportation. Chawla Medicos offer Ledipasvir 90 mg and Sofosbuvir 400 mg at affordable prices to clients.
- Low chance of side effects
- Extended shelf life
- Inhibitor of non-structural protein
Ledifos Tablets Ledipasvir Sofosbuvir 490mg
Ledifos is a fixed-dose combination tablet containing ledipasvir and sofosbuvir for oral administration.Each film, coated tablet contains Ledipasvir 90 mg and Sofosbuvir 400 mg.
INDICATIONS AND USAGE
Ledifos is indicated for the treatment of choronic hepatitis C (CHC) genotype 1 infection in adults.
DOSAGES AND ADMINISTRATION
Recommended Dosage in Adults
Ledifos is two-drug fixed-dose combination product that contained Ledipasvir 90 mg and Sofosbuvir 400 mg in a single tablet.The recommended dosages of Ledifos is one tablet taken orally once daily with or without food.
Duration of treatment
Relapse rates are affected by baseline host and viral factors and differ between treatment durations for certain subgroups. Below provides the recommended Ledifos treatment durations for treatment-naive and treatment-experienced patients and those with and without cirrhosis.
Recommended Treatment Duration for Ledifos in Patients with CHC Genotype 1 Patient Population
|Patient Population||Recommended Treatment Duration|
|Treatment-naive with or without cirrhosis||12 weeks*|
|Treatment-experienced** without cirrhosis||12 weeks|
|Treatment-experienced** with cirrhosis||24 weeks|
- Ledifos for 8 weeks can be considered in treatment-naÃ¯ve patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/ mL .
- Treatment-experienced patients who have failed treatment with either peginterferon alfa+ribavirin or an HCV protease inhibitor + peginterferon alfa + ribavirin
DOSAGES FORMS AND STERENGTHS
Ledifos is available as Green colored, oval shaped, film coated tablet debossed with an one side and plain on other side of the tablet.Each tablet contains Ledipasvir 90 mg and Sofosbuvir 400 mg.
No contraindications have been identified.
WARNINGS AND PRECAUTIONS
Serious Symptomatic Bradycardia When Coadministered with Amiodarone
Postmarketing cases of symptomatic bradycardia,as well as fetal cardiac arrest and cases requiring pacemaker intervention, have been reported when amiodarone is coadministered with Ledipasvir + Sofosbuvir. Bradycardia has generally occurred within hours to days,btus cases have been observed up to 2 weeks after initiating HCV treatment.Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone.Bradycardia generally resolved after discontinuation of HCV treatment.The mechanism for this effect is unknown.
Clinical Trials Experience
The most common adverse reactions (>=10%) were fatigue and headache Nausea, Diarrhea, Insomnia in subjects treated with 8, 12, or 24 weeks of Ledipasvir + Sofodbuvir.